Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2014

View Archived Issues

The Vanderbilt University prepares new mAChR modulators

Novel O-GlcNAcase inhibitors disclosed by Alectos and Merck & Co.

Washington University School of Medicine to assess EDI-200 in rare genetic disorder

Pharnext's PXT-3003 obtains FDA orphan drug status

Phase III results demonstrate noninferiority of tofacitinib to etanercept in psoriasis patients

NDA for Zacras fixed-dose combination tablet for hypertension approved in Japan

FDA grants orphan drug status to Chatham Therapeutics' hemophilia B treatment

New influenza treatment Avigan approved in Japan

Researchers in India design novel agents for MDR bacterial infections

Novartis divulges new S. aureus vaccines

Laminin-gamma2 as a novel biomarker for bladder cancer

First evaluation in humans of a new necrosis inhibitor, LC28-0126

Ajinomoto Pharmaceuticals obtains approval for valsartan/cilnidipine combination in Japan

Takeda Pharmaceutical receives positive CHMP opinion for Entyvio

Tapenta receives Japanese approval for cancer pain

Takelda combination tablets approved in Japan

Novel erythropoiesis-stimulating agent GC-1113 shows efficacy in humans

CHMP recommends approval of empagliflozin for type 2 diabetes

Siltuximab receives positive CHMP opinion supporting approval in multicentric Castleman's disease

Tivicay obtains approval in Japan for HIV

FDA grants fast track designation to NeuroVax for secondary progressive MS

KB-39 as novel peptidomimetic of Bcl-2 proteins for prostate cancer

Forxiga receives regulatory approval in Japan for type 2 diabetes

Japanese approval of Lusefi for type 2 diabetes

Mochida announces Japanese approval of Treprost for PAH

CytRx initiates phase III trial of aldoxorubicin for soft tissue sarcoma

Arrowhead conducting phase IIa study of ARC-520 to treat chronic HBV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...